Objectives: This prospective, pharmacokinetic study was done to investigate the impact of telaprevir plasma trough concentration (C trough ) in the early stage of treatment on the response to telaprevir-based triple therapy for chronic hepatitis C patients.
Introduction
Chronic hepatitis Cvirus (HCV) infection affects 170 million people and often causes cirrhosis and hepatocellular carcinoma (HCC). 1, 2 The ultimate goal of treatment for chronic hepatitis C is sustained virological response (SVR), which is defined as undetectable HCV RNA in serum 6 months after the termination of treatment. A 48 week combination of pegylated interferon-a (pegylated-IFNa) plus ribavirin is successful for only 45% of the 'difficult-to-treat' chronic hepatitis C patients infected with HCV genotype 1. 3 -6 Analysis of serum HCV dynamics has been shown to be useful for predicting the efficacy of antiviral treatment for chronic hepatitis C. Serum HCV RNA decline in the early stage of treatment (4 -12 weeks after the start of treatment) is associated with the likelihood of achieving an SVR. 3 -6 Rapid virological response (RVR; undetectable HCV RNA at week 4) and early virological response (EVR; undetectable HCV RNA at week 12) can provide guidance as to the likelihood of achieving SVR. 3 -6 Both pegylated-IFNa and ribavirin are indirect antiviral agents. They do not target a specific HCV protein or nucleic acid. In the USA, Canada, the European Union and Japan, telaprevir (VX950), an HCV non-structural 3/4A protease inhibitor, has recently been approved for the treatment of chronic hepatitis C genotype 1 and represents a new class of small molecules that are direct-acting antiviral agents (DAAs) that interfere with HCV replication. 7 -11 Telaprevirbased triple therapy combined with pegylated-IFNa and ribavirin has resulted in an improved SVR rate, when compared with pegylated-IFNa monotherapy and pegylated-IFNa plus ribavirin dual therapy. 12, 13 This is because telaprevir can produce a very rapid decline of the serum HCV RNA level immediately after the start of administration. 14 -18 A steady-state after multiple doses of orally administered telaprevir is reached after 3-7 days of administration. 7 -10 Therefore, we hypothesized that the telaprevir plasma trough concentration (C trough ) in the early stages of treatment (days [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] would have a great impact on the virological response of patients with HCV genotype 1 chronic hepatitis C. The aim of this prospective pharmacokinetic study was to investigate the relationship between the telaprevir C trough and the virological response of these patients.
Patients and methods

Study participants
This prospective study consisted of 70 Japanese patients infected with HCV genotype 1b, including 20 (28.6%) treatment-naive patients, 29 (41.4%) with prior relapse and 21 (30.0%) with prior non-response. Relapse was defined as undetectable HCV RNA during and at the end of treatment, but with HCV RNA positivity returning later. Non-response was defined as detectable HCV RNA for .24 weeks. All 50 prior relapse and non-response patients had a history of a 48 week pegylated-IFNa plus ribavirin combination treatment.
Telaprevir is contraindicated when combined with drugs that are highly dependent on cytochrome P450, family 3, subfamily A (CYP3A) for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening events.
10 Also, telaprevir is contraindicated when combined with drugs that strongly induce CYP3A and thus may lead to lower exposure and loss of telaprevir efficacy.
10 Based on the label instructions for each product, the drugs of patients taking contraindicated concomitant medications were switched to alternative drugs ≥3 months before the initiation of treatment.
All patients were recruited at Kyushu University Hospital. Exclusion criteria were as follows: positivity for antibody to HIV or positivity for hepatitis B surface antigen; clinical or biochemical evidence of hepatic decompensation; other causes of liver disease; excessive active alcohol consumption (.40 g/day of ethanol) or drug abuse; suspected HCC or active cancer at entry; chronic renal failure or estimated glomerular filtration rate of ≤50 mL/min; very poorly controlled heart diseases, pulmonary disorders, thyroid diseases or diabetes; depression or its history; history of a suicide attempt; pregnancy of either partner or planned during the study period; or treatment with antiviral or immunosuppressive agents prior to enrolment. The study was conducted in accordance with the ethical principles of the Declaration of Helsinki and was approved by the Ethics Committee of our hospital. Informed consent was obtained from each patient before enrolment. The study was registered as a clinical trial on the University Hospital Medical Information Network (ID 000009656).
Clinical assessment
Clinical parameters included serum albumin, creatinine, total bilirubin, alanine aminotransferase, aspartate aminotransferase, g-glutamyl transpeptidase, estimated glomerular filtration rate, white blood cell count, haemoglobin, platelet count and serum HCV markers. Blood samples were taken at baseline, days 3 and 7, and every week thereafter to week 24 during the treatment period. All parameters were measured at our hospital by standard laboratory techniques. Body mass index (BMI) was calculated as weight (kg) divided by the square of height (m 2 ). Liver biopsy at entry for 65 (92.9%) of the 70 patients was done by two or more experienced hepatologists. For each specimen, the stage of fibrosis (F0-4) and the grade of activity (A0 -3) were established according to METAVIR score. 19 
Determination of HCV markers
The baseline and follow-up tests for HCV viraemia were done by real-time PCR assay (COBAS w AmpliPrep/COBAS w TaqMan w HCV assay; Roche Molecular Systems, Inc., Branchburg, NJ, USA), with a lower limit of quantification of 15 IU/mL and an upper limit of quantification of 6.9×10
7 IU/mL (1.2 -7.8 log IU/mL referred to log 10 U/mL). HCV genotype and the core amino acid substitution at position 70 of the HCV gene were determined for each patient before treatment. HCV genotype was determined by sequence determination in the 5 ′ -non-structural region of the HCV genome followed by phylogenetic analysis. 17 Amino acid substitution at position 70 of the core region was analysed by direct sequencing, as reported previously. 18 
Genetic testing
Human genomic DNA was extracted from the peripheral blood of each patient. Genotyping by single nucleotide polymorphism (SNP) of the interleukin 28B (IL28B) (rs8099917) gene was done using the TaqMan w Allelic Discrimination Demonstration Kit (7500 Real-Time PCR System; Applied Biosystems, Foster City, CA, USA). 17 Patients were genotyped as TT, TG or GG at the polymorphic site. Genotyping by SNP of the inosine triphosphate pyrophosphatase (ITPA) (rs1127354) gene was done using the TaqMan w Allelic Discrimination Demonstration Kit. Patients were genotyped as CC, CA or AA at the polymorphic site.
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Antiviral treatment
All patients received 12 week triple therapy that included telaprevir (Telavic; Mitsubishi Tanabe Pharma, Osaka, Japan), pegylated-IFNa2b (PEG-Intron; MSD, Tokyo, Japan) and ribavirin (Rebetol; MSD) followed by a 12 week dual therapy that included pegylated-IFNa2b and ribavirin. Telaprevir (2250 mg/day) was administered orally three times a day, 750 mg after each meal at 8 h intervals. Pegylated-IFNa2b was injected subcutaneously once a week at a dose of 1.5 mg/kg. Ribavirin was given orally at a daily dose of 600-1000 mg based on body weight (600 mg for patients weighing ,60 kg, 800 mg for those weighing 60-80 kg and 1000 mg for those weighing .80 kg). Dose reduction from the starting dose (1.5 mg/kg/week) of pegylated-IFNa2b was done in a two-step process: first to 1 mg/kg/week, then to 0.5 mg/kg/week, if needed. If haemoglobin ,120 g/L was observed during treatment, the first dose reduction of ribavirin was by 200 mg/day and the second dose reduction was by an additional 200 mg/day when haemoglobin ,100 g/L was observed. The above protocol is that approved by the Japanese Ministry of Health, Labour and Welfare. 10 The telaprevir dose was reduced to 1500 mg/day (750 mg twice a day at a 12 h interval after meals) if a 1.5-2.0 times increase from baseline serum creatinine was observed. When serum creatinine was elevated to .2.0 times the baseline level, telaprevir was discontinued. If marked anorexia developed, the telaprevir dose could be reduced to 1500 mg/day. When grade 3 rash (≥50% of the body surface or with the appearance of substantial systemic signs of symptoms) developed, telaprevir was discontinued. However, the patients continued to receive pegylated-IFNa2b and ribavirin in all of these situations. All treatment was discontinued for patients with ,2 log 10 HCV RNA decline from baseline to week 12. 18 The triple therapy was discontinued if the haemoglobin, white blood cell count or platelet count fell below 80 g/L, 1×10 9 /L or 50×10 9 /L, respectively.
10
Efficacy of treatment
Successful treatment corresponded to SVR, defined as undetectable serum HCV RNA at 24 weeks after the end of treatment. EVR during the first 12 weeks of treatment was categorized as follows: RVR, undetectable HCV RNA at week 4; and complete EVR (cEVR), detectable HCV RNA at week 4, but undetectable at week 12. End-of-treatment response was defined as undetectable HCV RNA at the end of treatment. Relapse was defined as an end-of-treatment response, but non-SVR.
Assessment of drug adherence
The weekly dose of pegylated-IFNa2b and the daily doses of ribavirin were recorded by patients in an electronic dosing diary. Adherence to the Furusyo et al.
prescribed dosage of each drug was defined as the total dosage of the drug taken by the patient divided by the expected total drug dosage, with the expected total drug dose based on the actual treatment duration.
Determination of telaprevir C trough
Blood samples, collected early in the morning before the first daily dose of telaprevir, were drawn prior to each drug administration for determination of the telaprevir C trough , and the sampling window time from the last dose was calculated for each patient. Serial pharmacokinetic assessment of telaprevir C trough was done on days 3, 7 and 14 after the first administration of telaprevir. Samples from the vein ( 2.0 mL) were collected in tubes containing K3 EDTA. Each tube was immediately cooled in an ice water bucket, followed by centrifugation within 1 min after collection at 1500 g for 10 min at 48C. After 1 mL of the plasma (in duplicate) was mixed well with 50 mL of 10% formic acid to acidify the plasma and stabilize the telaprevir, the mixture was frozen on dry ice followed by storage at 2208C or below in a freezer.
The plasma telaprevir S-isomer (VX950) and R-isomer levels were simultaneously determined using a validated assay based on HPLC with mass spectrometry at a commercial laboratory (Mitsubishi Chemical Medience Corporation, Tokyo, Japan). The assay was validated over a telaprevir concentration range of 0.1-10 mg/mL for sensitivity, linearity, reproducibility, stability and recovery rate. The intra-and interassay precision (coefficient of variation %) met the criterion of ,15% and accuracy (relative error to the nominal concentration) results ranged within +15%.
Statistical analysis
Statistical analyses were performed using the SAS system, version 9.1.3 (SAS Institute, Cary, NC, USA). Continuous data are expressed as the mean (+SD) and compared using a t-test or Wilcoxon rank-sum test. Categorical variables are expressed as frequencies and percentages and compared using the x 2 test, Fisher's exact test or Mann-Whitney U-test. Telaprevir C trough is expressed as the mean (+SD). An area under the receiver operating characteristic curve (AUROC) analysis was conducted to evaluate the relationship between the telaprevir C trough and SVR. The cut-off values were selected from the receiver operating characteristic (ROC) curve to maximize the total sensitivity and specificity. We compared the AUROC of the two ROC curves using the method described by DeLong et al. 24 Univariate analysis was initially performed and variables with a significant association to SVR (P,0.2) were subsequently evaluated by stepwise logistic regression analysis that included all available variables in the database. Hosmer-Lemeshow lack-of-fit tests were performed to assess the fit of our final multivariate models. ORs with their 95% CIs were determined. A P value ,0.05 was regarded as statistically significant in all analyses.
Results
Patient characteristics
The patient characteristics are summarized in Table 1 . SVR patients had a significantly higher mean platelet count and serum albumin level than non-SVR patients. The IL28B SNP (rs8099917) TT allele was more frequent in SVR patients than in non-SVR patients. Non-TT (TG/GG) alleles were more frequent in non-SVR patients than in SVR patients. Prior relapse was significantly more frequent in SVR patients than in non-SVR patients. Prior non-response was significantly more frequent in non-SVR patients than in SVR patients.
None of the patients experienced severe anaemia before week 2 and only two discontinued telaprevir due to severe anaemia after week 2 (at weeks 4 and 10, respectively). Five others (7.1%) needed a dose reduction of telaprevir (from 2250 to 1500 mg/ day) due to severe anorexia after week 2 and two of them completely stopped telaprevir due to progressively severe anorexia (at weeks 6 and 12, respectively). Of the 70 patients studied, only these 7 were not able to complete the full telaprevir regimen. The remaining 63 patients continued to receive pegylated-IFNa2b and ribavirin. However, all 70 patients completed the first 2 weeks of the telaprevir regimen.
Virological outcome and response
Virological outcome and response during treatment were analysed on an intention-to-treat basis. RVR, cEVR, end-of-treatment response and SVR were found for 50 (71.4%), 18 (25.7%), 69 (98.6%) and 58 (82.9%) of the 70 studied patients, respectively: 11 patients relapsed (15.7%). Patients with RVR had a higher rate of SVR (90.0%, 45 of 50) than cEVR (72.2%, 13 of 18), but the difference did not reach significance (P ¼ 0.067). The mean serum HCV RNA level (+SD) at day 3 was significantly lower for RVR patients (2.2+0.8 log IU/mL) than for non-RVR patients (3.0+0.5 log IU/mL) (P,0.0001), whereas no significant difference in the level at day 3 was found between SVR (2.4+0.8 log IU/mL) and non-SVR (2.6+0.8 log IU/mL) patients (P ¼ 0.429).
Changes in telaprevir C trough by virological response Table 2 shows the plasma telaprevir C trough levels at each test point. The mean (+SD) sampling window time of a total of 210 plasma samples obtained from the 70 patients was 10.2+1.1 h after the last dose. No significant differences in the mean window times were found between SVR and non-SVR patients. Stratification by virological outcome revealed differences in the telaprevir C trough levels of SVR and non-SVR patients (Figure 1 ). At each point (days 3, 7 and 14), the mean plasma telaprevir C trough level of the SVR patients (2.748, 2.733 and 2.999 mg/mL, respectively) was significantly higher than that of non-SVR patients (1.616, 1.788 and 2.314 mg/mL, respectively) (P,0.0001, P¼0.0004 and P¼0.0380, respectively).
Stratification by EVR revealed differences in the telaprevir C trough levels of RVR (n¼50) and non-RVR (n¼20) patients. At each point (days 3, 7 and 14), the mean plasma telaprevir C trough level of RVR patients (2.661, 2.580 and 3.064 mg/mL, respectively) was higher than that of non-RVR patients (2.429, 2.541 and 2.800 mg/mL, respectively), but without statistical significance.
The rate of SVR of pre-cirrhosis (F3) and cirrhosis (F4) patients (78.6%, 22 of 28) was lower than that of patients with mild liver fibrosis (F0-2) (83.8%, 31 of 37), but the difference was not significant (P¼0.591). We conducted an additional analysis of the telaprevir C trough of the F3 and F4 patients, classified by SVR (Figure 2 ). At the day 3, 7 and 14 test points, the mean plasma telaprevir C trough level of the SVR patients (2.616, 2.609 and 3.063 mg/mL, respectively) was higher than that of non-SVR patients (1.492, 1.701 and 2.099 mg/mL, respectively). The high telaprevir C trough in the early stage (days 3, 7 and 14) was related to SVR of the patients with progressive liver fibrosis (P¼0.0021, P¼0.0043 and P¼0.0334, respectively).
Changes in telaprevir C trough by baseline factors and drug adherence
Univariate analyses found no significant differences in plasma telaprevir C trough between men and women, IL28B TT and non-TT alleles, or core wild or mutated HCV. Moreover, we did not find any significant differences in telaprevir C trough levels for patient ROC curve analysis of telaprevir C trough for predicting an SVR Table 3 shows the results of ROC curve analysis conducted to evaluate the ability of plasma telaprevir C trough to predict SVR. The AUROC value at day 3 was the highest and differed significantly from those at days 7 (P¼ 0.0001) and 14 (P,0.0001). The optimal telaprevir C trough threshold was 1.924 mg/mL at day 3, which suggests that it is the best predictor of SVR.
Variables correlated with SVR
In order to identify variables significantly associated with achieving an SVR, variables with P,0.2 in univariate analysis in Table 1 (age, white blood cell count, platelet count, serum albumin, aspartate aminotransferase, previous treatment outcome, IL28B SNP, ITPA SNP, discontinuation of pegylated-IFNa2b and ribavirin, discontinuation of triple therapy, RVR and cEVR) and telaprevir C trough at day 3 were evaluated by multivariate logistic regression. This analysis of possible predictors of SVR extracted higher telaprevir C trough at day 3 (OR 1.012 by 0.001 mg/mL, 95% CI 1.001-1.060, P,0.0001) and IL28B (rs8099917) TTallele (OR 6.16 versus non-TT alleles, 95% CI 2.54-17.9, P,0.0001).
Discussion
This study shows the usefulness of telaprevir concentration monitoring for patients receiving telaprevir-based triple therapy and its utility for predicting the virological response of patients with HCV genotype 1b. After a single dose of telaprevir, the mean half-life is 4 h. At steady-state, the half-life is 9-11 h. When 750 mg of telaprevir is administered three times a day at 8 h intervals, a steady-state is reached from 3 to 7 days after the start of administration. 7 -10 Our findings showed significant differences in the plasma telaprevir C trough levels of SVR and non-SVR patients in the early stage (days 3 -14) of triple therapy, suggesting that early telaprevir monitoring would help the tailoring of treatment duration and that it could be useful as an early predictor of treatment failure. To date, no studies have assessed the relative role played by telaprevir C trough on the virological efficacy of telaprevirbased triple therapy. Our study showed that higher telaprevir C trough in the early stage is related to both RVR and SVR. We also showed that a significant decline of the serum HCV RNA level at day 3 is related to RVR, which leads to SVR. This phenomenon is a virological feature that clearly shows the rapid action of the DAA telaprevir.
Two patients stopped telaprevir due to adverse effects in this study. To avoid telaprevir-resistant variants of HCV, telaprevir dose reduction should not be permitted. This study included five patients who had the dose of telaprevir reduced due to adverse effects after week 2. In this study, 10% (7 of 70) of the patients were unable to complete the telaprevir regimen. This must be taken into account when interpreting the results. This is because our study is not a sponsor-initiated clinical trial, but an investigatorinitiated clinical research project. However, all of the 70 patients studied completed the full telaprevir regimen of the first 2 weeks. For this reason, we focused on the analysis of the association between telaprevir C trough in the early stage and on SVR.
Treatment of chronic hepatitis C has two goals. The first is sustained eradication of HCV. The second is to prevent progression Samples were collected early in the morning before the first daily dose of telaprevir.
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The sampling window time from the last dose was calculated for each patient. The P values were 0.477, 0.093 and 0.541 at days 3, 7 and 14, respectively, with no significant differences between SVR and non-SVR patients.
Telaprevir concentration in HCV infection 487 JAC to cirrhosis, HCC or decompensated liver disease. We previously showed a significant association between SVR and a lower rate of HCC in a prospective, multicentre study. 2 However, a large cohort study (n¼ 497) in France has provided significant information for the management of DAA-based triple therapy for HCV-infected cirrhotic patients, showing that the safety profile is poor in a real-life setting. 25 Therefore, treatment should be initiated promptly for patients with advanced fibrosis. We recruited 28 patients with progressive liver fibrosis (F3 and F4), of whom 22 achieved SVR and 6 had treatment failure. In this subgroup, we found a difference in the telaprevir C trough in the early stage of treatment related to virological response. These findings give us a tool for the early prediction of treatment, which will help prevent unnecessary exposure to the strong drugs used for patients with advanced fibrosis. Although our results are based on a limited number of patients, they indicate that drug monitoring during DAA treatment with the next generation of drugs will be helpful, even for patients with progressive liver fibrosis.
Gastrointestinal tract absorption probably influences telaprevir pharmacokinetics. Absorption through the gastrointestinal tract is influenced by the fat content of food. Compared with standard food ingestion (533 kcal, 189 kcal of fat), the telaprevir concentration decreased by 73% -83% when administered under fasting conditions. 7 -10 For our patients, telaprevir administration immediately after each meal was recommended, as instructed in the telaprevir prescription literature.
10 Unfortunately, we did not record food consumption in terms of calories or constituents and thus cannot perform a more detailed analysis of the differences in the telaprevir C trough .
The IL28B gene-related SNP on chromosome 19 is the most important baseline predictor of SVR after treatment with pegylatedIFNa plus ribavirin for chronic hepatitis C. 6,15 -17 This study found the IL28B allele to be a significant, independent pretreatment factor for achieving SVR with this telaprevir-based regimen. Several classes of DAAs are under development and it is expected that, when used in combination with pegylated-IFNa plus ribavirin, these new drugs will improve SVR and decrease the required duration of treatment. 26 The IL28B allele has an influence on early viral kinetics, even during treatment with interferon-free DAA Furusyo et al.
regimens. Interferon-free regimens produce no difference within 6 days after the start of treatment, but a significant difference in HCV RNA reduction after day 7 has been documented for patients with IL28B SNP (rs12979860) CC versus the non-CC alleles. 27 The host IL28B allele has also been shown to affect the spontaneous clearance of HCV infection. 28 Thus, IL28B genotyping will continue to play an important role in determining the likelihood of anti-HCV treatment response.
A limitation of this study is that the sample size might provide inadequate statistical power to detect definitive differences in the telaprevir C trough between SVR and non-SVR. However, this was a prospective study and included consecutive data on the telaprevir C trough in the early stage of telaprevir-based triple therapy. To the best of our knowledge, ours is the first significant pharmacokinetic study of telaprevir C trough . Also, we studied only patients with HCV genotype 1b. Significant differences in virological response and drug mutations between HCV genotypes 1a and 1b have been reported for DAA-based treatment. 29 We are uncertain whether our finding that higher telaprevir C trough can lead to the achievement of SVR applies to the response of other HCV genotypes. Further study will be required to clarify the importance of telaprevir C trough on treatment outcome. Our patients received a fixed 24 week triple therapy. Telaprevir has been approved since September 2011 for use in Japan only for the treatment of genotype 1 chronic hepatitis C with a high HCV RNA level (≥5.0 log IU/mL). Also, the duration of triple therapy is 24 weeks, with all three agents for the first 12 weeks and then pegylated-IFNa2b plus ribavirin dual therapy for the remaining 12 weeks. 10 In contrast, in Europe, the USA and Canada, telaprevir must be administered with pegylated-IFNa and ribavirin for all patients for 12 weeks, followed by a response-guided regimen of either 12 or 36 additional weeks of pegylated-IFNa and ribavirin, depending on the early viral response. 7 -9 Differences in the duration of treatment after the end of telaprevir administration could influence relapse, but not end-of-treatment response. Therefore, our findings on efficacy as judged by the early-stage telaprevir C trough should hold, even for prolonged regimens of pegylated-IFNa2b and ribavirin. To ensure compliance, each patient was instructed before and during treatment that telaprevir should be administered three times a day, after each meal at an 8 h interval. However, our data showed that 10 h was the mean window time of the telaprevir C trough . This difference in timing must be considered when judging the findings. The difference may have occurred because the patients had difficulty adjusting to taking meals in the middle of the night. This is problematic in any investigator-initiated clinical research.
In conclusion, our study shows that the telaprevir C trough threshold at day 3 is highly predictive of SVR in patients undergoing a telaprevir-based treatment regimen. The results provide important new insights that will be useful for developing DAA-based regimens.
